Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

895 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Guidelines for the diagnosis and management of multiple myeloma 2011.
Bird JM, Owen RG, D'Sa S, Snowden JA, Pratt G, Ashcroft J, Yong K, Cook G, Feyler S, Davies F, Morgan G, Cavenagh J, Low E, Behrens J; Haemato-oncology Task Force of British Committee for Standards in Haematology (BCSH) and UK Myeloma Forum. Bird JM, et al. Among authors: yong k. Br J Haematol. 2011 Jul;154(1):32-75. doi: 10.1111/j.1365-2141.2011.08573.x. Epub 2011 May 14. Br J Haematol. 2011. PMID: 21569004 Free article. Review. No abstract available.
Updates to the guidelines for the diagnosis and management of multiple myeloma.
Pratt G, Jenner M, Owen R, Snowden JA, Ashcroft J, Yong K, Feyler S, Morgan G, Cavenagh J, Cook G, Low E, Stern S, Behrens J, Davies F, Bird J. Pratt G, et al. Among authors: yong k. Br J Haematol. 2014 Oct;167(1):131-3. doi: 10.1111/bjh.12926. Epub 2014 May 7. Br J Haematol. 2014. PMID: 24801672 Free article. No abstract available.
High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial.
Cook G, Williams C, Brown JM, Cairns DA, Cavenagh J, Snowden JA, Ashcroft AJ, Fletcher M, Parrish C, Yong K, Cavet J, Hunter H, Bird JM, Chalmers A, O'Connor S, Drayson MT, Morris TC; National Cancer Research Institute Haemato-oncology Clinical Studies Group. Cook G, et al. Among authors: yong k. Lancet Oncol. 2014 Jul;15(8):874-85. doi: 10.1016/S1470-2045(14)70245-1. Epub 2014 Jun 16. Lancet Oncol. 2014. PMID: 24948586 Clinical Trial.
Time to redefine Myeloma.
Pratt G, Bowcock S, Chantry A, Cook G, Jackson G, Lai M, Low E, Mulholland N, Owen R, Rabin N, Ramasamy K, Snowden JA, Streetly M, Wechalekar A, Yong K, Bird J. Pratt G, et al. Among authors: yong k. Br J Haematol. 2015 Oct;171(1):1-10. doi: 10.1111/bjh.13620. Epub 2015 Jul 27. Br J Haematol. 2015. PMID: 26221971 Free article.
Multiple myeloma and physical activity: a scoping review.
Smith L, McCourt O, Henrich M, Paton B, Yong K, Wardle J, Fisher A. Smith L, et al. Among authors: yong k. BMJ Open. 2015 Nov 27;5(11):e009576. doi: 10.1136/bmjopen-2015-009576. BMJ Open. 2015. PMID: 26614625 Free PMC article. Review.
The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myeloma.
Brown S, Hinsley S, Ballesteros M, Bourne S, McGarry P, Sherratt D, Flanagan L, Gregory W, Cavenagh J, Owen R, Williams C, Kaiser M, Low E, Yong K; Myeloma UK Clinical Trials Network. Brown S, et al. Among authors: yong k. BMC Hematol. 2016 May 17;16:14. doi: 10.1186/s12878-016-0053-9. eCollection 2016. BMC Hematol. 2016. PMID: 27190631 Free PMC article.
895 results